IDEXX Total Revenue vs Total Current Liabilities Analysis

0J8P Stock   416.54  3.95  0.96%   
IDEXX Laboratories financial indicator trend analysis is infinitely more than just investigating IDEXX Laboratories recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether IDEXX Laboratories is a good investment. Please check the relationship between IDEXX Laboratories Total Revenue and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.

Total Revenue vs Total Current Liabilities

Total Revenue vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of IDEXX Laboratories Total Revenue account and Total Current Liabilities. At this time, the significance of the direction appears to have strong relationship.
The correlation between IDEXX Laboratories' Total Revenue and Total Current Liabilities is 0.74. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of IDEXX Laboratories, assuming nothing else is changed. The correlation between historical values of IDEXX Laboratories' Total Revenue and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of IDEXX Laboratories are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Total Revenue i.e., IDEXX Laboratories' Total Revenue and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.74
Relationship DirectionPositive 
Relationship StrengthSignificant

Total Revenue

Total revenue comprises all receipts IDEXX Laboratories generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Total Current Liabilities

Total Current Liabilities is an item on IDEXX Laboratories balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of IDEXX Laboratories are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from IDEXX Laboratories' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into IDEXX Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.Selling General Administrative is likely to drop to about 187 M in 2024. Tax Provision is likely to drop to about 109.4 M in 2024
 2021 2022 2023 2024 (projected)
Total Revenue3.2B3.4B3.7B3.8B
Depreciation And Amortization104.6M111.9M114.9M120.7M

IDEXX Laboratories fundamental ratios Correlations

0.950.750.730.990.490.910.950.630.980.760.480.98-0.320.970.47-0.920.820.960.770.680.690.140.540.880.6
0.950.710.590.950.570.820.970.460.960.850.330.96-0.410.90.46-0.860.860.870.880.690.710.10.590.870.75
0.750.710.190.720.860.520.770.270.690.430.480.69-0.280.760.78-0.650.920.780.730.550.940.750.670.770.56
0.730.590.190.71-0.220.890.590.750.720.60.330.730.050.74-0.01-0.750.20.690.190.570.03-0.370.140.510.09
0.990.950.720.710.490.90.950.590.990.780.410.98-0.370.960.41-0.910.810.930.790.630.680.090.510.880.65
0.490.570.86-0.220.490.170.61-0.140.470.310.220.48-0.540.480.65-0.350.890.480.790.260.950.740.510.550.64
0.910.820.520.890.90.170.840.670.920.760.30.92-0.190.930.27-0.970.550.830.50.720.38-0.080.330.70.42
0.950.970.770.590.950.610.840.40.970.820.30.97-0.430.930.46-0.890.860.870.830.710.730.180.530.850.69
0.630.460.270.750.59-0.140.670.40.520.250.760.530.180.560.3-0.550.270.730.230.320.19-0.140.320.550.14
0.980.960.690.720.990.470.920.970.520.840.311.0-0.370.960.39-0.940.790.890.780.710.640.060.50.850.65
0.760.850.430.60.780.310.760.820.250.84-0.030.84-0.320.750.12-0.770.580.60.640.670.39-0.140.360.660.57
0.480.330.480.330.410.220.30.30.760.31-0.030.330.080.390.5-0.230.410.70.310.090.470.30.390.50.04
0.980.960.690.730.980.480.920.970.531.00.840.33-0.410.960.37-0.930.80.90.780.680.650.060.470.840.63
-0.32-0.41-0.280.05-0.37-0.54-0.19-0.430.18-0.37-0.320.08-0.41-0.27-0.050.3-0.5-0.22-0.630.11-0.48-0.040.2-0.11-0.55
0.970.90.760.740.960.480.930.930.560.960.750.390.96-0.270.46-0.930.770.920.680.750.660.20.50.820.52
0.470.460.78-0.010.410.650.270.460.30.390.120.50.37-0.050.46-0.430.690.560.520.560.740.740.760.560.52
-0.92-0.86-0.65-0.75-0.91-0.35-0.97-0.89-0.55-0.94-0.77-0.23-0.930.3-0.93-0.43-0.68-0.82-0.62-0.76-0.53-0.09-0.42-0.74-0.58
0.820.860.920.20.810.890.550.860.270.790.580.410.8-0.50.770.69-0.680.80.940.50.970.520.650.830.78
0.960.870.780.690.930.480.830.870.730.890.60.70.9-0.220.920.56-0.820.80.710.60.720.250.560.860.48
0.770.880.730.190.790.790.50.830.230.780.640.310.78-0.630.680.52-0.620.940.710.390.860.260.550.770.87
0.680.690.550.570.630.260.720.710.320.710.670.090.680.110.750.56-0.760.50.60.390.360.190.640.620.41
0.690.710.940.030.680.950.380.730.190.640.390.470.65-0.480.660.74-0.530.970.720.860.360.690.610.730.68
0.140.10.75-0.370.090.74-0.080.18-0.140.06-0.140.30.06-0.040.20.74-0.090.520.250.260.190.690.480.280.19
0.540.590.670.140.510.510.330.530.320.50.360.390.470.20.50.76-0.420.650.560.550.640.610.480.80.61
0.880.870.770.510.880.550.70.850.550.850.660.50.84-0.110.820.56-0.740.830.860.770.620.730.280.80.68
0.60.750.560.090.650.640.420.690.140.650.570.040.63-0.550.520.52-0.580.780.480.870.410.680.190.610.68
Click cells to compare fundamentals

IDEXX Laboratories Account Relationship Matchups

IDEXX Laboratories fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets1.8B2.3B2.4B2.7B3.3B3.4B
Other Current Liab276.5M355.2M396.4M364.7M372.4M391.0M
Total Current Liabilities725.3M582.8M763.6M1.2B951.5M999.1M
Total Stockholder Equity177.5M632.1M690.0M608.7M1.5B1.6B
Property Plant And Equipment Net533.8M555.2M587.7M649.5M817.7M858.6M
Net Debt897.3M524.6M779.2M1.2B613.4M644.1M
Retained Earnings1.6B2.2B2.9B3.6B4.4B4.7B
Accounts Payable72.2M74.6M116.1M110.2M110.6M116.2M
Cash90.3M383.9M144.5M112.5M453.9M476.6M
Non Current Assets Total1.2B1.2B1.5B1.6B1.8B1.9B
Non Currrent Assets Other299.0M337.2M397.4M425.6M333.0M349.6M
Cash And Short Term Investments90.3M383.9M144.5M112.5M453.9M476.6M
Net Receivables307.5M374.7M425.6M490.9M529.5M556.0M
Common Stock Shares Outstanding87.5M86.7M86.6M84.6M84.0M94.9M
Liabilities And Stockholders Equity1.8B2.3B2.4B2.7B3.3B3.4B
Inventory195.0M209.9M269.0M367.8M380.3M399.3M
Other Current Assets86.8M94.2M116.6M130.2M131.5M75.1M
Other Stockholder Equity(1.4B)(1.5B)(2.2B)(2.9B)(2.9B)(2.8B)
Total Liab1.7B1.7B1.7B2.1B1.8B1.9B
Total Current Assets679.6M1.1B955.7M1.1B1.5B1.6B
Non Current Liabilities Total929.3M1.1B983.6M902.2M823.8M865.0M
Intangible Assets58.5M52.5M99.0M97.7M84.5M66.7M
Short Long Term Debt Total987.7M908.5M923.7M1.3B1.1B1.1B
Short Term Debt304.0M67.7M168.4M674.4M344.8M212.2M
Accumulated Other Comprehensive Income(46.2M)(53.6M)(53.5M)(77.8M)(71.2M)(67.6M)
Common Stock10.6M10.6M10.7M10.7M10.8M9.2M
Current Deferred Revenue41.5M42.6M40.0M37.9M37.2M25.0M
Good Will239.7M243.3M359.3M361.8M366.0M218.6M
Other Assets240.2M289.6M325.2M1.01.151.09
Other Liab162.9M143.5M121.0M106.6M95.9M115.4M
Net Tangible Assets(120.7M)336.2M231.6M149.3M171.7M180.2M
Long Term Debt499.6M599.5M858.5M775.2M891.5M711.1M
Deferred Long Term Liab108.6M116.1M122.4M119.9M137.9M115.7M
Property Plant Equipment614.5M646.3M692.8M768.1M883.3M648.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for IDEXX Stock Analysis

When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.